AU2007278748B2 - Method of producing a population of cells - Google Patents
Method of producing a population of cells Download PDFInfo
- Publication number
- AU2007278748B2 AU2007278748B2 AU2007278748A AU2007278748A AU2007278748B2 AU 2007278748 B2 AU2007278748 B2 AU 2007278748B2 AU 2007278748 A AU2007278748 A AU 2007278748A AU 2007278748 A AU2007278748 A AU 2007278748A AU 2007278748 B2 AU2007278748 B2 AU 2007278748B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- neutrophil
- population
- culture medium
- progenitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 151
- 210000004027 cell Anatomy 0.000 claims abstract description 525
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 340
- 210000000130 stem cell Anatomy 0.000 claims abstract description 186
- 102000004127 Cytokines Human genes 0.000 claims abstract description 83
- 108090000695 Cytokines Proteins 0.000 claims abstract description 83
- 239000001963 growth medium Substances 0.000 claims abstract description 74
- 210000004102 animal cell Anatomy 0.000 claims abstract description 36
- 238000012258 culturing Methods 0.000 claims abstract description 36
- 230000003068 static effect Effects 0.000 claims abstract description 34
- 239000006143 cell culture medium Substances 0.000 claims abstract description 32
- 239000001301 oxygen Substances 0.000 claims abstract description 25
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 25
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 24
- 230000036542 oxidative stress Effects 0.000 claims abstract description 23
- 230000012010 growth Effects 0.000 claims abstract description 16
- 238000012546 transfer Methods 0.000 claims abstract description 15
- 239000002243 precursor Substances 0.000 claims description 50
- 239000002609 medium Substances 0.000 claims description 39
- 238000000338 in vitro Methods 0.000 claims description 25
- 108010041111 Thrombopoietin Proteins 0.000 claims description 23
- 230000001965 increasing effect Effects 0.000 claims description 17
- 210000004700 fetal blood Anatomy 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000012737 fresh medium Substances 0.000 claims description 12
- 102000036693 Thrombopoietin Human genes 0.000 claims description 11
- 238000013019 agitation Methods 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 11
- 239000011886 peripheral blood Substances 0.000 claims description 11
- 210000005087 mononuclear cell Anatomy 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000000394 mitotic effect Effects 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000033001 locomotion Effects 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 5
- 108010002386 Interleukin-3 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 25
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 25
- 210000001167 myeloblast Anatomy 0.000 description 18
- 208000004235 neutropenia Diseases 0.000 description 16
- 230000010261 cell growth Effects 0.000 description 14
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 13
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 230000003394 haemopoietic effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000003887 myelocyte Anatomy 0.000 description 11
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 9
- 210000001237 metamyelocyte Anatomy 0.000 description 9
- 210000004765 promyelocyte Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 210000004976 peripheral blood cell Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101710160107 Outer membrane protein A Proteins 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- 210000004524 haematopoietic cell Anatomy 0.000 description 3
- 210000003593 megakaryocyte Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009668 clonal growth Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 108700014844 flt3 ligand Proteins 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 thiol compounds Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 206010060935 Alloimmunisation Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100030886 Complement receptor type 1 Human genes 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000004770 Fusariosis Diseases 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 206010051919 Fusarium infection Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000005763 Thrombopoietin Receptors Human genes 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940081858 plasmalyte a Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83285406P | 2006-07-24 | 2006-07-24 | |
| US60/832,854 | 2006-07-24 | ||
| PCT/AU2007/001019 WO2008011664A1 (en) | 2006-07-24 | 2007-07-23 | Method of producing a population of cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007278748A1 AU2007278748A1 (en) | 2008-01-31 |
| AU2007278748B2 true AU2007278748B2 (en) | 2013-08-15 |
Family
ID=37689856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007278748A Active AU2007278748B2 (en) | 2006-07-24 | 2007-07-23 | Method of producing a population of cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8173427B2 (enExample) |
| EP (1) | EP2044197B8 (enExample) |
| JP (1) | JP5543778B2 (enExample) |
| AU (1) | AU2007278748B2 (enExample) |
| CA (1) | CA2658639C (enExample) |
| WO (1) | WO2008011664A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009086596A1 (en) * | 2008-01-08 | 2009-07-16 | The University Of Queensland | Method of producing a population of cells |
| WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| GB201618106D0 (en) | 2016-10-26 | 2016-12-07 | Lift Biosciences Ltd | Cancer-killing cells |
| JP2020512830A (ja) * | 2017-03-17 | 2020-04-30 | ロングボート アムニオティクス アーベーＬｏｎｇｂｏａｔ Ａｍｎｉｏｔｉｃｓ Ａｂ | 細胞ストレス及び活性酸素を低減するための方法、システム、因子、および培地 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080806A2 (en) * | 2002-03-18 | 2003-10-02 | National Jewish Medical And Research Center | Method for production of neutrophils and uses therefor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992000376A1 (en) * | 1990-06-25 | 1992-01-09 | Immunex Corporation | Mast cell growth factor |
| JPH06508528A (ja) * | 1992-03-23 | 1994-09-29 | ネクセル セラピューティクス インコーポレーテッド | インビトロ由来ヒト好中球前駆体細胞 |
| SG47030A1 (en) | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
| JPH08127541A (ja) * | 1994-10-31 | 1996-05-21 | Chugai Pharmaceut Co Ltd | 新規制癌剤 |
| AU2260097A (en) * | 1996-03-12 | 1997-10-01 | Life Technologies, Inc. | Hematopoietic cell culture nutrient supplement |
| AUPO540997A0 (en) * | 1997-03-04 | 1997-03-27 | Ludwig Institute For Cancer Research | Models for haematopoiesis |
| US6190913B1 (en) | 1997-08-12 | 2001-02-20 | Vijay Singh | Method for culturing cells using wave-induced agitation |
| DK1783222T3 (da) * | 1998-10-23 | 2012-07-09 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| DK1226233T3 (da) * | 1999-08-05 | 2011-10-03 | Abt Holding Co | Multipotente voksne stamceller og fremgangsmåder til isolering heraf |
| WO2004063195A1 (en) * | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| WO2004072242A2 (en) * | 2003-02-05 | 2004-08-26 | Millennium Pharmaceuticals, Inc. | Screening of compounds for hematological disorder treatment |
| WO2004072264A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof |
| US20060205071A1 (en) * | 2003-07-17 | 2006-09-14 | Gamida-Cell Ltd. | Methods for ex-vivo expanding stem/progenitor cells |
-
2007
- 2007-07-23 WO PCT/AU2007/001019 patent/WO2008011664A1/en not_active Ceased
- 2007-07-23 JP JP2009521064A patent/JP5543778B2/ja active Active
- 2007-07-23 AU AU2007278748A patent/AU2007278748B2/en active Active
- 2007-07-23 US US12/375,098 patent/US8173427B2/en active Active
- 2007-07-23 EP EP07784668.1A patent/EP2044197B8/en active Active
- 2007-07-23 CA CA2658639A patent/CA2658639C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080806A2 (en) * | 2002-03-18 | 2003-10-02 | National Jewish Medical And Research Center | Method for production of neutrophils and uses therefor |
Also Published As
| Publication number | Publication date |
|---|---|
| US8173427B2 (en) | 2012-05-08 |
| EP2044197A1 (en) | 2009-04-08 |
| AU2007278748A1 (en) | 2008-01-31 |
| JP2009544290A (ja) | 2009-12-17 |
| US20100151569A1 (en) | 2010-06-17 |
| EP2044197B1 (en) | 2017-11-22 |
| JP5543778B2 (ja) | 2014-07-09 |
| WO2008011664A1 (en) | 2008-01-31 |
| EP2044197A4 (en) | 2011-01-05 |
| CA2658639A1 (en) | 2008-01-31 |
| CA2658639C (en) | 2015-08-04 |
| EP2044197B8 (en) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007278748B2 (en) | Method of producing a population of cells | |
| AU2009203893B2 (en) | Method of producing a population of cells | |
| Sandstrom et al. | Effects of CD34+ cell selection and perfusion on ex vivo expansion of peripheral blood mononuclear cells | |
| CN101490246B (zh) | 自吸脂后脂肪吸取物分离及纯化造血干细胞 | |
| JP2006525013A (ja) | 血液幹細胞の数の増幅のための装置および方法 | |
| WO2008149129A1 (en) | Cell expansion | |
| WO2007024441A2 (en) | Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof | |
| KR20170045355A (ko) | 조혈모 세포 의학에서 유용한 방법 및 화합물 | |
| US9862928B2 (en) | Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells | |
| Wang et al. | Mouse mesenchymal stem cells can support human hematopoiesis both in vitro and in vivo: the crucial role of neural cell adhesion molecule | |
| US9206389B2 (en) | Culture for expanding stem cells ex-vivo | |
| US20250313804A1 (en) | Methods for expanding natural killer cells (nk cells) | |
| US20060084170A1 (en) | Cytokine-free growth and maintenance of progenitor cells | |
| Soleimani et al. | Expansion of Non-Enriched Cord Blood Stem/Progenitor Cells CD34+ CD38-Using Liver Cells | |
| Charbord | Stem cells for grafting | |
| Wang et al. | ĐFerrata Storti Foundation | |
| Holyoake et al. | CD34 selection and ex vivo expansion of haemopoietic progenitor cells: a review of laboratory methodology | |
| Bender | In Vitro Proliferation and Differentiation of CD34+ Cells to Neutrophils | |
| HK1140513B (en) | Lithium stimulation of cord blood stem cell proliferation and growth factor production | |
| HK1140513A1 (en) | Lithium stimulation of cord blood stem cell proliferation and growth factor production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO INCLUDE CO-INVENTOR TIMMINS, NICHOLAS M. |
|
| FGA | Letters patent sealed or granted (standard patent) |